Mobile Menu - OpenMobile Menu - Closed

Palmer Statement on FDA Approval of Exondys 51

September 20, 2016
Press Release

September 20, 2016

For Immediate Release

Media Contact: Cate Cullen (202)225-4921

Palmer Statement on FDA Approval of Exondys 51

Washington, DC – On Monday, the Food and Drug Administration (FDA) approved a drug for Duchenne muscular dystrophy more than 100 days after the agency’s legally mandated decision date. The drug, Exondys 51 (eteplirsen), is the first of its kind and will benefit patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. Congressman Gary Palmer (R-AL) offered the following statement:

“This was a victory for those affected by Duchenne muscular dystrophy and their families,” said Palmer. “With the FDA approval of Exondys 51, some people impacted by Duchenne have new hope for an improved quality of life and a better tomorrow. I applaud all those who have advocated for this medical advancement, including one of my constituents, Gabe Griffin. While this medical advancement does not treat the cause of Gabe’s muscle degeneration, it is a step in the right direction towards creating and approving the drug that will.”

###

 

Issues: